The first sickle hemoglobin polymerization inhibitor approved in Europe, Oxbryta increases hemoglobin levels and reduces sickling and hemolysis – the cause of long-term complications of sickle cell ...
Over the course of voxelotor treatment, hemoglobin levels and hemolysis markers improved, with results sustained over the treatment period. Adolescents and adults with SCD saw improved hemoglobin ...
Inclacumab is a novel P-selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises (VOCs) and readmissions due to VOCs in patients with sickle cell disease GBT601 is a ...
A single treatment of an investigational CRISPR/Cas9-based cell therapy could provide durable disease control for nearly all patients with transfusion-dependent beta-thalassemia and sickle cell ...
In a recent review published in Nutrients, researchers assessed nutrition-related studies involving sickle cell disease (SCD) patients, particularly those in Africa. SCD, a congenital blood condition, ...
Researchers at Drexel University have identified the physical forces in red blood cells and blood vessels underlying the painful symptoms of sickle cell disease. Their experiment, the first to answer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results